Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 10/20 | 0.43 |
| ▸ | BCHE | P06276 | 9/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 9/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 9/20 | 0.43 |
| ▸ | DHODH | Q02127 | 2/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9971755 | 0.83 | ACHE (0.46) | ACHEBCHEGRIN1GRIN2ADHODH | |
| SCHEMBL72673 | 0.80 | KDM4E (0.47) | ADORA3ADORA2AACHEBCHEGRIN1 | |
| SCHEMBL71734 | 0.78 | CLK1 (0.51) | ADORA3ADORA2AHTR3AHRH4ACHE | |
| SCHEMBL13737248 | 0.77 | DHODH (0.44) | ACHEBCHEGRIN1GRIN2ADHODH | |
| SCHEMBL29663483 | 0.76 | HTT (0.64) | ACHEBCHEGRIN1GRIN2ADHODH | |
| SCHEMBL8900878 | 0.76 | HTT (0.64) | ACHEBCHEGRIN1GRIN2ADHODH | |
| SCHEMBL29441517 | 0.72 | HTT (0.68) | ADORA3ADORA2AHTR3AHRH4ACHE | |
| SCHEMBL3335843 | 0.72 | HSP90AB1 (0.57) | HTR3AHRH4HSP90AB1 | |
| SCHEMBL21500731 | 0.72 | HTT (0.68) | ADORA3ADORA2AHTR3AHRH4ACHE | |
| SCHEMBL27223540 | 0.72 | DCPS (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122916-A1 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-05-17 | — | — | US | disclosed |
| US-8129402-B2 | Screening molecules with anti-prion activity: kits, methods and screened molecules | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-03-06 | — | — | US | disclosed |
| US-20110092483-A1 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2011-04-21 | — | — | US | disclosed |
| US-20070031821-A1 | Screening molecules with anti-prion activity: kits, methods and screened molecules | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS ) (FR) | 2007-02-08 | — | — | US | disclosed |
| EP-1551992-B1 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | CENTRE NAT RECH SCIENT (FR) | 2006-12-27 | — | — | EP | disclosed |
| US-20060172337-A1 | Screening molecules with anti-prion activity: kits, methods and screened molecules | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-08-03 | — | — | US | disclosed |
| EP-1551992-A2 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004035813-A2 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122916-A1 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | PRPF6, PRNP, TDP1 | ADORA3 985/4885ADORA2A 1964/4885HTR3A 4038/4885 |
| US-20110092483-A1 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | ATXN2L, ATXN10, CLN6 | ADORA3 1609/4885ADORA2A 2529/4885HTR3A 3680/4885 |
| US-20070031821-A1 | Screening molecules with anti-prion activity: kits, methods and screened molecules | ATXN2L, ATXN10, CLN6 | ADORA3 1609/4885ADORA2A 2529/4885HTR3A 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.